{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:20:21Z","timestamp":1787498421253,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41401-025-01695-4","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:45:28Z","timestamp":1762184728000},"page":"677-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Formyl peptide receptor 2 is a potential biomarker and therapeutic target for inflammatory bowel disease"],"prefix":"10.1038","volume":"47","author":[{"given":"Wen-sheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652\u201364.","journal-title":"N Engl J Med"},{"key":"1695_CR2","first-page":"375","volume":"22","author":"J Mayberry","year":"2013","unstructured":"Mayberry J. The history of 5-ASA compounds and their use in ulcerative colitis \u2013 trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013;22:375\u20137.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1695_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","volume":"52","author":"HC Chan","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141\u201350.","journal-title":"J Gastroenterol"},{"key":"1695_CR4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ibd\/izaa045","volume":"26","author":"GT Ho","year":"2020","unstructured":"Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of inflammation and gut repair in IBD: translational steps towards complete mucosal healing. Inflamm Bowel Dis. 2020;26:1131\u201343.","journal-title":"Inflamm Bowel Dis"},{"key":"1695_CR5","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Va\u0148\u00e1sek T, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779\u201389.","journal-title":"Lancet"},{"key":"1695_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/1756283X14558193","volume":"8","author":"A Amiot","year":"2015","unstructured":"Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66\u201382.","journal-title":"Therap Adv Gastroenterol"},{"key":"1695_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12876-021-02074-z","volume":"22","author":"J Li","year":"2022","unstructured":"Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, et al. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: Results from the explore study. BMC Gastroenterol. 2022;22:44.","journal-title":"BMC Gastroenterol"},{"key":"1695_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107879","volume":"227","author":"D Panigrahy","year":"2021","unstructured":"Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol Ther. 2021;227:107879.","journal-title":"Pharmacol Ther"},{"key":"1695_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","volume":"36","author":"M Perretti","year":"2015","unstructured":"Perretti M, Leroy X, Bland EJ, Montero-Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci. 2015;36:737\u201355.","journal-title":"Trends Pharmacol Sci"},{"key":"1695_CR10","doi-asserted-by":"crossref","unstructured":"Doyle R, Godson C. Chapter 5 - Endogenous antiinflammatory and proresolving lipid mediators in renal disease. In: Goligorsky M, editor. Regenerative Nephrology (Second Edition). United States: Academic Press; 2022. p 55\u201367.","DOI":"10.1016\/B978-0-12-823318-4.00009-3"},{"key":"1695_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1757-3","volume":"21","author":"H Zhang","year":"2017","unstructured":"Zhang H, Lu Y, Sun G, Teng F, Luo N, Jiang J, et al. The common promoter polymorphism rs11666254 downregulates FPR2\/ALX expression and increases risk of sepsis in patients with severe trauma. Crit Care. 2017;21:171.","journal-title":"Crit Care"},{"key":"1695_CR12","doi-asserted-by":"publisher","first-page":"G487","DOI":"10.1152\/ajpgi.00042.2011","volume":"301","author":"D Prescott","year":"2011","unstructured":"Prescott D, McKay DM. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol. 2011;301:G487\u201397.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1695_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"1695_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"1695_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1124\/mol.104.004309","volume":"66","author":"M Nanamori","year":"2004","unstructured":"Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, et al. A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004;66:1213\u201322.","journal-title":"Mol Pharmacol"},{"key":"1695_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1124\/mol.107.037564","volume":"72","author":"C Zhou","year":"2007","unstructured":"Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, et al. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007;72:976\u201383.","journal-title":"Mol Pharmacol"},{"key":"1695_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295\u2013309.","journal-title":"Nat Protoc"},{"key":"1695_CR18","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/femsre\/fux035","volume":"41","author":"R Mart\u00edn","year":"2017","unstructured":"Mart\u00edn R, Chain F, Miquel S, Motta JP, Vergnolle N, Sokol H, et al. Using murine colitis models to analyze probiotics-host interactions. FEMS Microbiol Rev. 2017;41:S49\u2013S70.","journal-title":"FEMS Microbiol Rev"},{"key":"1695_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378.","journal-title":"Eur Urol"},{"key":"1695_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","volume":"67","author":"I Arijs","year":"2018","unstructured":"Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, et al. Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67:43\u201352.","journal-title":"Gut"},{"key":"1695_CR21","doi-asserted-by":"publisher","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","volume":"4","author":"I Arijs","year":"2009","unstructured":"Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE. 2009;4:e7984.","journal-title":"PLoS ONE"},{"key":"1695_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejphar.2018.06.025","volume":"833","author":"JG Filep","year":"2018","unstructured":"Filep JG, Sekheri M, El Kebir D. Targeting formyl peptide receptors to facilitate the resolution of inflammation. Eur J Pharmacol. 2018;833:339\u201348.","journal-title":"Eur J Pharmacol"},{"key":"1695_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1042\/BST20220271","volume":"50","author":"RM Lucas","year":"2022","unstructured":"Lucas RM, Luo L, Stow JL. ERK1\/2 in immune signalling. Biochem Soc Trans. 2022;50:1341\u201352.","journal-title":"Biochem Soc Trans"},{"key":"1695_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/molecules22030455","volume":"22","author":"HQ He","year":"2017","unstructured":"He HQ, Ye RD. The formyl peptide receptors: diversity of ligands and mechanism for recognition. Molecules. 2017;22:455.","journal-title":"Molecules"},{"key":"1695_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","volume":"23","author":"NR West","year":"2017","unstructured":"West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579\u201389.","journal-title":"Nat Med"},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/gutjnl-2012-303333","volume":"62","author":"N Planell","year":"2013","unstructured":"Planell N, Lozano JJ, Mora-Buch R, Masamunt MC, Jimeno M, Ord\u00e1s I, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2013;62:967\u201376.","journal-title":"Gut"},{"key":"1695_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","volume":"178","author":"JC Martin","year":"2019","unstructured":"Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-tnf therapy. Cell. 2019;178:1493\u2013508.e20.","journal-title":"Cell"},{"key":"1695_CR28","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ajg.2011.83","volume":"106","author":"G Toedter","year":"2011","unstructured":"Toedter G, Li K, Marano C, Ma K, Sague S, Huang CC, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106:1272\u201380.","journal-title":"Am J Gastroenterol"},{"key":"1695_CR29","doi-asserted-by":"publisher","first-page":"e1006951","DOI":"10.1371\/journal.pcbi.1006951","volume":"15","author":"S Pavlidis","year":"2019","unstructured":"Pavlidis S, Monast C, Loza MJ, Branigan P, Chung KF, Adcock IM, et al. I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. PLoS Comput Biol. 2019;15:e1006951.","journal-title":"PLoS Comput Biol"},{"key":"1695_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92\u2013101.","journal-title":"Nature"},{"key":"1695_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41401-022-00944-0","volume":"44","author":"WS Yang","year":"2023","unstructured":"Yang WS, Wang JL, Wu W, Wang GF, Yan J, Liu Q, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. Acta Pharmacol Sin. 2023;44:19\u201331.","journal-title":"Acta Pharmacol Sin"},{"key":"1695_CR32","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.185.9.1693","volume":"185","author":"T Takano","year":"1997","unstructured":"Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997;185:1693\u2013704.","journal-title":"J Exp Med"},{"key":"1695_CR33","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.4049\/jimmunol.0903526","volume":"184","author":"N Dufton","year":"2010","unstructured":"Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2010;184:2611\u20139.","journal-title":"J Immunol"},{"key":"1695_CR34","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.4049\/jimmunol.1090139","volume":"186","author":"N Dufton","year":"2011","unstructured":"Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. Corrections: anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2011;186:2684.","journal-title":"J Immunol"},{"key":"1695_CR35","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1172\/JCI65569","volume":"123","author":"K Chen","year":"2013","unstructured":"Chen K, Liu M, Liu Y, Yoshimura T, Shen W, Le Y, et al. Formyl peptide receptor 2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest. 2013;123:1694\u2013704.","journal-title":"J Clin Invest"},{"key":"1695_CR36","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.1096\/fj.201901163R","volume":"33","author":"D Birkl","year":"2019","unstructured":"Birkl D, O\u2019Leary MN, Quiros M, Azcutia V, Schaller M, Reed M, et al. Formyl peptide receptor 2 regulates monocyte recruitment to promote intestinal mucosal wound repair. FASEB J. 2019;33:13632\u201343.","journal-title":"FASEB J"},{"key":"1695_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16753-z","volume":"7","author":"C Xu","year":"2017","unstructured":"Xu C, Ghali S, Wang J, Shih DQ, Ortiz C, Mussatto CC, et al. CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway. Sci Rep. 2017;7:16351.","journal-title":"Sci Rep"},{"key":"1695_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","volume":"19","author":"A Herrero-Cervera","year":"2022","unstructured":"Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022;19:177\u201391.","journal-title":"Cell Mol Immunol"},{"key":"1695_CR39","doi-asserted-by":"publisher","first-page":"631821","DOI":"10.3389\/fimmu.2021.631821","volume":"12","author":"E P\u00e9rez-Figueroa","year":"2021","unstructured":"P\u00e9rez-Figueroa E, \u00c1lvarez-Carrasco P, Ortega E, Maldonado-Bernal C. Neutrophils: many ways to die. Front Immunol. 2021;12:631821.","journal-title":"Front Immunol"},{"key":"1695_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd1453","volume":"7","author":"C Trilleaud","year":"2021","unstructured":"Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, et al. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Sci Adv. 2021;7:eabd1453.","journal-title":"Sci Adv"},{"key":"1695_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105550","volume":"155","author":"A Binienda","year":"2020","unstructured":"Binienda A, Fichna J, Salaga M. Recent advances in inflammatory bowel disease therapy. Eur J Pharmacol Sci. 2020;155:105550.","journal-title":"Eur J Pharmacol Sci"},{"key":"1695_CR42","first-page":"000229","volume":"4","author":"M Mm","year":"2020","unstructured":"Mm M. Certain inflammatory changes in scabies stressed patients treated with permethrin 5%. Virol Immunol J. 2020;4:000229.","journal-title":"Virol Immunol J"},{"key":"1695_CR43","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41401-025-01525-7","volume":"46","author":"WS Yang","year":"2025","unstructured":"Yang WS, Liu Q, Li Y, Li GY, Lin S, Li J, et al. Oral FPR2\/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease. Acta Pharmacol Sin. 2025;46:1958\u201373.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01695-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01695-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01695-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:02:36Z","timestamp":1771959756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01695-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01695-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}